Pasireotide; octreotide LAR 30mg; lanreotide ATG 120mg
Проводит Новартис Фарма АГ
Страница компанииA Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01137682/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 198 чел. во всех странах исследования.
- Плановая дата окончания (02.2017) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 7
Критерии включения
- Patients with written informed consent prior to any study related activity
- Patients who had inadequately controlled acromegaly as defined by a mean GH concentration of a 5-point profile over a 2-hour period > 2.5 µg/L and sex- and age-adjusted IGF-1 > 1.3 x upper limit of normal (ULN)
- Patients who had been treated with maximum indicated doses of octreotide LAR or lanreotide ATG for at least 6 months prior to visit 1 (screening). The maximum indicated dose for octreotide LAR was 30mg and for lanreotide ATG iwas120 mg
- Patients who had a diagnosis of pituitary micro- or macro adenoma. Patients could have been previously submitted to surgery
- Patients who completed the 24-week treatment period in core according to the requirements of the core study protocol or corresponding amendments could enter extension
Критерии невключения
- Patients who had received pasireotide (SOM 230) prior to enrolment
- Concomitant treatment with Growth Hormone Receptor (GHR)-antagonist or dopamine agonists unless concomitant treatment was discontinued 8 weeks prior to visit 1 (screening)(8 weeks wash out period). Such patients must have been treated with octreotide LAR 30 mg or lanreotide ATG 120 mg monotherapy continuously for a minimum of 6 months prior to starting combination therapy and they should have been inadequately controlled on monotherapy.
- Patients who had compression of the optic chiasm causing acute clinically significant visual field defects
- Patients who required a surgical intervention for relief of any sign or symptom associated with tumor compression
- Patients who had received pituitary irradiation within 10 years prior to visit 1 (screening).
- Patients who had undergone major surgery/surgical therapy for any cause within 4 weeks prior to visit 1 (screening).
- Patients who were hypothyroid and not adequately treated with a stable dose of thyroid hormone replacement therapy
Источник: ClinicalTrials.gov, NCT01137682 · запись обновлена в реестре 5 апреля 2018.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 14
- Percentage of Participants With a Reduction of Mean GH Levels to < 2.5 µg/L and Normalization of Sex- and Age-adjusted IGF-1. — At 24 weeks
Цель исследования
This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01137682 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.